Ahmed Saeed Yahya
Ahmed Saeed Yahya has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
Shakil Khawaja
Dr Yahya is a Consultant Psychiatrist at the Priory Hospital North London; Dr Khawaja is a Consultant Psychiatrist and ECT Clinical Lead at North East London NHS Foundation Trust; Dr Naguib is a Locum Consultant Psychiatrist at North East London NHS Foundation Trust, and was previously a Consultant in Psychiatric Intensive Care at Barnet, Enfield and Haringey Mental Health NHS Trust
4 shared publicationsAbdulelah Albukhari
1 shared publication- Achouak Boutalbi1 shared publication
- Ahmad Abbas
Chest Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt
1 shared publication Ahmed Atta
OTC kuwait, Nephrology, Ff, Kuwait
1 shared publicationAhmed Sami
OTC kuwait, Nephrology, Ff, Kuwait
1 shared publication
Latest Publications
- 13 August 2024
- Published by Taylor & Francis
- p. 173-207
Lipid-Based Nanocarriers for Brain Delivery of Bioactives in the Treatment of Neurodegenerative Disorders
Neurodegenerative diseases include diverse conditions (e.g., Parkinson’s disease and Alzheimer’s disease) in which ongoing loss of neurons and glial cells is implicated. They lead to impaired motor and cognitive functions. Although there is an advancement in therapeutic options impacting the pathogenetic mechanisms of the disease, the BBB exerts a physiological barrier that hinders their access to the brain. Thereby, novel drug delivery approaches have been considered to enhance CNS targeting and bioavailability. There is increasing evidence that lipid-based nanocarriers (e.g., liposomes) may improve brain targeting and ease BBB transportation. Nevertheless, no authorized nanoformula targets the CNS till now. We aim to summarize the relevant literature about the different types of lipid-based nanocarriers and the findings of the preclinical and clinical trials conducted so far through systematic and manual searches in PubMed. Hence, it may be inspiring to translate this approach into clinical practice and benefit from their pharmacokinetic characteristics. Moreover, we attempt to highlight the challenges and future outlooks for their implementation in clinical practice. Overall, it is still early for these applications to be translated into clinical practice due to several reasons, including safety concerns; the lack of simple formulas that can be eligible and allow affordable, large-scale production; and the absence of reliable, high-quality, and strong evidence. We suggest that there is a necessity for appropriately designed controlled trials and standardized analytical methods.
- 13 August 2024
- Published by Taylor & Francis
- p. 173-207
Lipid-Based Nanocarriers for Brain Delivery of Bioactives in the Treatment of Neurodegenerative Disorders
Neurodegenerative diseases include diverse conditions (e.g., Parkinson’s disease and Alzheimer’s disease) in which ongoing loss of neurons and glial cells is implicated. They lead to impaired motor and cognitive functions. Although there is an advancement in therapeutic options impacting the pathogenetic mechanisms of the disease, the BBB exerts a physiological barrier that hinders their access to the brain. Thereby, novel drug delivery approaches have been considered to enhance CNS targeting and bioavailability. There is increasing evidence that lipid-based nanocarriers (e.g., liposomes) may improve brain targeting and ease BBB transportation. Nevertheless, no authorized nanoformula targets the CNS till now. We aim to summarize the relevant literature about the different types of lipid-based nanocarriers and the findings of the preclinical and clinical trials conducted so far through systematic and manual searches in PubMed. Hence, it may be inspiring to translate this approach into clinical practice and benefit from their pharmacokinetic characteristics. Moreover, we attempt to highlight the challenges and future outlooks for their implementation in clinical practice. Overall, it is still early for these applications to be translated into clinical practice due to several reasons, including safety concerns; the lack of simple formulas that can be eligible and allow affordable, large-scale production; and the absence of reliable, high-quality, and strong evidence. We suggest that there is a necessity for appropriately designed controlled trials and standardized analytical methods.
- Open Access
- 14 June 2023
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (Supplement)
#3945 ACUTE KIDNEY INJURY (AKI) AMONG COVID-19 POSITIVE PATIENTS INCREASES THE RISK OF MORTALITY: A SINGLE CENTER EXPERIENCE
Background and Aims: Renal complications of COVID-19 are not yet well studied. We aimed to evaluate the prevalence of acute kidney injury (AKI) among positive COVID-19 hospitalize cases and explore its impact on patient outcomes. Method: 586 hospitalized patients with COVID-19 were retrospectively evaluated. of them, 267 (45.5%) developed AKI- classified according to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines- compared with 319 (54.5%) patients without AKI. Results: Most cases were males (72.7% vs. 69.7%), and their ages ranged (60.8± 14 vs. 51.7± 16 years). Comorbid conditions significantly predominant among the AKI group were diabetes mellitus (64 vs. 42.9%), hypertension (72.6% vs. 43.5%), and ischemic heart disease (25% vs. 14.7%). Fever, cough, shortness of breath, and dehydration were the main presentations among the AKI group, and they had significant radiological findings concordant with COVID-19 (86.8% vs. 59.8%). Sepsis, volume depletion, shock, arrhythmias, and ARDS were significantly higher in the AKI group. Anticoagulation (85% vs. 59.2%), vasopressors, plasma infusions, antimicrobials, and steroids were more frequently used in the AKI group. Acute respiratory failure requiring mechanical ventilation and the overall mortality rate were significantly higher in the AKI group (62.3% vs. 32.9% and 63.2%. vs. 31.1%, respectively). Conclusion: AKI associated with severe COVID-19 was more frequent than reports from Chinese, European, and North American cohorts. AKI risk factors included COVID-19 comorbidities like hypertension, diabetes, mechanical ventilation, male gender, and older age. Mortality was high in this population, especially elderly patients, and in those who develop KDIGO stage 3 AKI.
- 14 June 2023
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (Supplement)
Open Access#3945 ACUTE KIDNEY INJURY (AKI) AMONG COVID-19 POSITIVE PATIENTS INCREASES THE RISK OF MORTALITY: A SINGLE CENTER EXPERIENCE
Background and Aims: Renal complications of COVID-19 are not yet well studied. We aimed to evaluate the prevalence of acute kidney injury (AKI) among positive COVID-19 hospitalize cases and explore its impact on patient outcomes. Method: 586 hospitalized patients with COVID-19 were retrospectively evaluated. of them, 267 (45.5%) developed AKI- classified according to the Kidney Disease Improving Global Outcomes (KDIGO) guidelines- compared with 319 (54.5%) patients without AKI. Results: Most cases were males (72.7% vs. 69.7%), and their ages ranged (60.8± 14 vs. 51.7± 16 years). Comorbid conditions significantly predominant among the AKI group were diabetes mellitus (64 vs. 42.9%), hypertension (72.6% vs. 43.5%), and ischemic heart disease (25% vs. 14.7%). Fever, cough, shortness of breath, and dehydration were the main presentations among the AKI group, and they had significant radiological findings concordant with COVID-19 (86.8% vs. 59.8%). Sepsis, volume depletion, shock, arrhythmias, and ARDS were significantly higher in the AKI group. Anticoagulation (85% vs. 59.2%), vasopressors, plasma infusions, antimicrobials, and steroids were more frequently used in the AKI group. Acute respiratory failure requiring mechanical ventilation and the overall mortality rate were significantly higher in the AKI group (62.3% vs. 32.9% and 63.2%. vs. 31.1%, respectively). Conclusion: AKI associated with severe COVID-19 was more frequent than reports from Chinese, European, and North American cohorts. AKI risk factors included COVID-19 comorbidities like hypertension, diabetes, mechanical ventilation, male gender, and older age. Mortality was high in this population, especially elderly patients, and in those who develop KDIGO stage 3 AKI.
- Open Access
- 1 April 2023
- Published by Wiley in Progress in Neurology and Psychiatry
- Vol. 27 (2) , 24-26
Psychiatric disorder in DYT1 dystonia
- 1 April 2023
- Published by Wiley in Progress in Neurology and Psychiatry
- Vol. 27 (2) , 24-26
Open AccessPsychiatric disorder in DYT1 dystonia
- 20 May 2021
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 23 (3)
Electroconvulsive Therapy as a Treatment for Somatization Disorder
Is ECT an effective treatment option for severe and refractory manifestations of somatization disorder? In this review, the authors investigate the efficacy, safety, and tolerability of ECT in somatization disorder.
- 20 May 2021
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 23 (3)
Electroconvulsive Therapy as a Treatment for Somatization Disorder
Is ECT an effective treatment option for severe and refractory manifestations of somatization disorder? In this review, the authors investigate the efficacy, safety, and tolerability of ECT in somatization disorder.
- 6 August 2020
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 22 (4)
Stalking and COVID-19
- 6 August 2020
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 22 (4)
Stalking and COVID-19
- 9 July 2020
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 22 (4)
COVID-19 and Perinatal Psychiatry
- 9 July 2020
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 22 (4)
COVID-19 and Perinatal Psychiatry